Intrexon Corp (XON) 50.16 $XON Intrexon (XON) Shares

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intrexon Corp (XON) 50.16 $XON

Intrexon (XON) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 6:07AM CST
Intrexon (XON) Shares March Higher, Can It Continue?
XON: 50.16 (+0.66)

Can Intrexon Corp's Jaw-Dropping Growth Continue after Tuesday's 20% Jump?
Maxx Chatsko, The Motley Fool - Motley Fool - Thu Mar 05, 8:12AM CST
Image source: John Goode/ Flickr . Who said fame only lasts for 15 minutes? Already on a tear entering 2015, synthetic biology leader Intrexon roared higher after reporting full-year 2014 earnings earlier this week. A little over two months...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)

Why Intrexon Corp Catapulted Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 03, 3:10PM CST
Source: Intrexon Corporation Although we don't believe in   timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Intrexon...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)

Intrexon ups revenues 338% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 9:27AM CST

XON: 50.16 (+0.66)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:16AM CST

MDR: 3.32 (-0.05), ONCY: 0.90 (-0.15), PLUG: 2.97 (+0.01), OCN: 8.91 (+0.24), XON: 50.16 (+0.66), TEDU: 10.24 (+0.21), BIOC: 3.10 (-0.26), LL: 33.32 (-0.51), MNKD: 5.47 (-0.26), CYCC: 1.05 (-0.01), CYTX: 1.11 (-0.05), DATE: 5.06 (-0.04), TSEM: 17.50 (-0.31), LEAF: 48.59 (-1.19), FNJN: 2.42 (-0.10), AMCO: 1.28 (-0.02)

Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PR Newswire - Tue Mar 03, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has received a positive recommendation from the Data Review Committee (DRC) to continue enrolling into the company's Phase 2 study evaluating SGX942, a first-in-class innate defense regulator (IDR), as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck cancer. Following DRC review of available data on the subjects enrolled in the trial, the committee recommended that enrollment include an additional 20 subjects randomized into either a single SGX942 dose group or the placebo group to allow for a more targeted assessment of the drug's potential effect and to inform final dose selection in this patient population.
XON: 50.16 (+0.66)

Synthetic Biologics to Present at the 27th Annual ROTH Conference
PR Newswire - Tue Mar 03, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, Chief Executive Officer, is scheduled to present at the 27th Annual ROTH Conference being held on March 8-11, 2015 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time).
SYN: 2.45 (+0.10), XON: 50.16 (+0.66)

Intrexon's (XON) CEO R.J. Kirk on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Mar 02, 8:38PM CST

XON: 50.16 (+0.66)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:37PM CST

GWRE: 52.98 (-0.06), MDR: 3.32 (-0.05), ST: 55.99 (-0.99), GRUB: 42.32 (-0.87), ISDR: 9.35 (-0.65), EWQ: 25.81 (-0.51), XON: 50.16 (+0.66), OPWR: 9.89 (-0.53), NSAM: 24.48 (-0.27), NE: 15.19 (-0.78)

Intrexon (XON) Stock Climbs in After-Hours Trading Today Following Earnings Release
at The Street - Mon Mar 02, 3:30PM CST
Intrexon (XON) shares are rising in after-hours trading after beating analysts' fourth quarter earnings and revenue expectations.
XON: 50.16 (+0.66)

Intrexon beats by $0.10, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:12PM CST

XON: 50.16 (+0.66)

Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Mon Mar 02, 3:05PM CST
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its fourth quarter and full year results for 2014.
XON: 50.16 (+0.66)

Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015
PR Newswire - Mon Mar 02, 5:57AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-005 for the treatment of Pertussis will be highlighted at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), April 25-28, in Copenhagen, Denmark. Two posters will be presented under the Respiratory Infections category all four days at ECCMID on 50 ePoster stations, as follows:
SYN: 2.45 (+0.10), XON: 50.16 (+0.66)

Intrexon to buy Okanagan Specialty Fruits in the first half of 2015
M2 - Mon Mar 02, 4:11AM CST
Synthetic biology company Intrexon (NYSE:XON) Friday reported an agreement to acquire Okanagan Specialty Fruits (OSF) for USD31m in Intrexon common stock plus USD10m in upfront cash.
XON: 50.16 (+0.66)

Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Mar 01, 4:35PM CST

MBI: 9.25 (-0.12), GWRE: 52.98 (-0.06), CODI: 16.42 (-0.10), MDR: 3.32 (-0.05), HTGC: 14.60 (+0.04), NBR: 12.69 (-0.44), NTRI: 18.37 (-0.51), XON: 50.16 (+0.66), STKL: 9.88 (+0.05), OPWR: 9.89 (-0.53), CZR: 9.63 (-0.53), PANW: 140.73 (-2.41), INN: 13.45 (-0.35), CMLS: 3.02 (-0.01), MTDR: 21.23 (-1.39), ARNA: 4.32 (+0.09), MCEP: 6.09 (-0.17), SLXP: 158.01 (+0.57), BALT: 1.52 (-0.04), MYL: 55.44 (-1.25), SN: 13.47 (-0.42), EPIQ: 17.04 (-0.47), CHUY: 22.48 (-0.64), DTSI: 32.74 (-0.89), PRAA: 49.58 (-0.39), HALO: 15.20 (-0.19), CIM: 3.13 (-0.06), CKEC: 30.28 (-0.13)

This Billionaire CEO Just Made Another Biotech Acquisition -- and Hardly Anyone Noticed
Maxx Chatsko, The Motley Fool - Motley Fool - Sat Feb 28, 1:08PM CST
Investors have rushed to acquire shares of synthetic biology company Intrexon in the first two months of 2015. Most of the enthusiasm stems from a recent partnership with the University of Texas MD Anderson Cancer Center and Ziopharm to...
ZIOP: 13.38 (-0.43), MRK: 56.84 (-1.14), XON: 50.16 (+0.66)

Intrexon: Back-End Economics Could Generate Huge Upside
Chris Bunge - Seeking Alpha - Fri Feb 27, 11:20AM CST
"I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning." --Steve Jobs As an investor important characteristics of a company lie in the product or service they...
ZIOP: 13.38 (-0.43), XON: 50.16 (+0.66)

Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 32.97 (-0.74), CASM: 1.35 (-0.02), AMRN: 1.78 (+0.11), XON: 50.16 (+0.66), OSIR: 18.40 (+1.46), CPIX: 6.95 (+0.20), AMED: 27.62 (-0.73), CTIC: 2.65 (-0.07), INSY: 57.69 (+0.08), ECYT: 6.21 (-0.04), CMRX: 39.33 (-1.46), KYTH: 53.13 (+3.13), TRIB: 18.74 (+0.22), GALE: 1.88 (-0.12), ARNA: 4.32 (+0.09), XLRN: 40.55 (-0.79), ACRX: 8.74 (-0.27), ENDP: 87.03 (-0.68), DPLO: 28.94 (-1.54), SLXP: 158.01 (+0.57), PPHM: 1.63 (+0.06), MYL: 55.44 (-1.25), CBPO: 82.88 (+1.08), RGEN: 25.07 (-0.71), HALO: 15.20 (-0.19), ALIM: 5.11 (+0.21), ACHN: 11.39 (+0.40), GERN: 3.50 (-0.28), DARA: 0.80 (-0.02), SCMP: 15.64 (+0.49), ICPT: 266.14 (+4.96), CDXS: 3.70 (-0.29), PCRX: 96.63 (-1.77), PBYI: 232.83 (-10.34), FOLD: 8.49 (-0.16)

Expert Briefing on Biotech Stocks - Lexicon Pharma, Sunesis Pharma, Navidea Biopharma, Tekmira Pharma, and Intrexon
PR Newswire - Thu Feb 19, 7:35AM CST
Editor Note: For more information about this release, please scroll to bottom.
NAVB: 1.67 (-0.03), LXRX: 1.17 (+0.05), XON: 50.16 (+0.66), TKMR: 18.76 (-0.93), SNSS: 2.26 (-0.03)

Don't Mimic Warren Buffett - Cramer's Mad Money (2/18/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Feb 19, 6:35AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, February 18. Cramer started the show by mentioning that piggybacking or mimicking someone's strategy of buying stocks is a bad idea. The market moved on...
WFM: 55.66 (-0.49), NKE: 96.91 (-1.55), GMCR: 126.24 (-2.81), SLXP: 158.01 (+0.57), XON: 50.16 (+0.66), WWAV: 41.79 (-0.63), SBUX: 92.21 (-1.42), UA: 74.80 (-0.99), VDSI: 22.58 (-0.73), IBM: 158.50 (-2.68), DE: 90.26 (-0.20), SIX: 45.97 (-0.79), KKD: 21.01 (-0.64), BRK.B: 145.28 (-0.78), BRK.A: 218,811.00 (-689.00), FTNT: 33.60 (-0.64), HTA: 25.77 (-1.53)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 48

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 117

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Gaotu Techedu's Q3 Results: A Look at AI-Driven Growth

Updated Category News Views 56

Gaotu Techedu to Unveil Q3 Results Mark your calendars, folks—Gaotu Techedu Inc. (NYSE: GOTU) is gearing up to dish out its third quarter financial results on November 25, 2026. As usual, these numbers will slide out before the U.S. markets spring into action. It's one of those moments when investors like us strap in and watch for any movement that might toss our...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 79

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 382

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Atomera Preps for Key Craig-Hallum Conference

Updated Category News Views 59

Unpacking the NYC Gathering Alight, let's comb through the moving parts here. Atomera Inc., ticker NASDAQ: ATOM for those eyeing the dance of numbers, is all set to step into the limelight at the 17th Annual Craig-Hallum Alpha Select Conference on November 17, 2026. This shindig isn't just another date on the calendar; it's a strategic haunt where Atomera will rub...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 421

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 87

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading

Top 5 Most Recently Viewed Articles

Choice Hotels Unveils Comprehensive Sustainability Efforts

Updated Category News Views 387

Choice Hotels International Launches 2024 Sustainability Report Choice Hotels International, Inc. (NYSE: CHH), a leading global lodging franchisor, has officially released its 2024 Sustainability Report, showcasing its ongoing commitment to environmental sustainability. The report highlights the company's innovative approaches to reducing its carbon footprint and...

Continue Reading
Revitalizing Communities Through Skilled Trades Initiatives

Updated Category News Views 157

Revitalizing Communities Through Skilled Trades Initiatives In an important moment for many towns across America that are striving for renewal, a new initiative has emerged to shine a light on the necessity of skilled trades. The campaign, titled Careers in Manufacturing, is aimed at highlighting how vital these trades are for both local economies and the workforce on the...

Continue Reading
Color Me Mine Celebrates Growth and Franchise Success

Updated Category News Views 344

Color Me Mine Achieves Remarkable Mid-Year Growth Color Me Mine, a leading paint-your-own pottery franchise, is excited to announce significant growth through its studio expansion and franchisee success. The brand is witnessing a thriving landscape of opportunities, fueled by enthusiastic franchise owners who are making their mark in various communities. Studio Expansion...

Continue Reading
Earnings Insights: Companies Set to Report Soon

Updated Category News Views 202

Upcoming Earnings Reports for Major Companies As the earnings season approaches, investors and analysts eagerly anticipate the financial results from several prominent companies. This article highlights some of the key players expected to announce their quarterly results. Companies Reporting Before the Market Opens UP Fintech Holding (TIGR) UP Fintech Holding is projected...

Continue Reading
Cogent Biosciences Shares Insights at Prestigious Healthcare Event

Updated Category News Views 207

Cogent Biosciences Highlights Participation in Major Healthcare Conference Cogent Biosciences, Inc. (Nasdaq: COGT), a pioneering biotechnology company, is ready to showcase its innovative approach to precision medicine at the highly regarded J.P. Morgan Healthcare Conference. Taking place in San Francisco, this annual event is a crucial platform for industry leaders to...

Continue Reading